Paul D'AGostino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul D'AGostino has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Herrmann
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
1 shared publication - Manuel Einsiedler
Technische Universität Dresden
1 shared publication - Norbert Sträter
Leipzig University
1 shared publication - Renato H.‐J. Weiße
Leipzig University
1 shared publication - Rolf Müller
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Saarbrücken Germany
1 shared publication - Tobias Alexander Marius Gulder
Department of Natural Product Biotechnology, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Department of Pharmacy at Saarland University, PharmaScienceHub (PSH), 66123 Saarbrücken, Germany
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Chemo-enzymatic Total Synthesis and Combinatorial Biosynthesis of Maculalactones
Maculalactones are bioactive γ-butyrolactone natural products with promising antifouling properties, yet their limited availability constrains further development. Here, we report the identification and characterization of the key biosynthetic enzymes MacE and MacF from the maculalactone (mac) biosynthetic gene cluster in Nodularia sp. NIES-3585. In vitro reconstitution confirmed that MacE catalyzes acyloin condensation between phenylpyruvic acids, while MacF mediates subsequent fusion of the MacE product with cinnamoyl-CoA derivatives. Structure-guided engineering improved enzyme solubility, enabling systematic substrate scope expansion. Through a one-pot enzymatic synthesis, we synthesized 13 maculalactone derivatives with yields reaching more than 96%, while a complementary combinatorial biosynthesis approach enabled the incorporation of sterically demanding indole moieties, thereby significantly expanding the maculalactone structural space. Bioactivity screening against A549 lung adenocarcinoma cells revealed moderate cytotoxicity (IC₅₀ = 20.82–56.64 μM), with methylation of phenol groups significantly enhancing activity. Several analogs exhibited notable antibacterial activity against clinically relevant Gram-positive pathogens, including Streptococcus pneumoniae. Our work provides a sustainable platform for producing structurally diverse maculalactones, laying the foundation for future biomedical applications.
- 14 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessChemo-enzymatic Total Synthesis and Combinatorial Biosynthesis of Maculalactones
Maculalactones are bioactive γ-butyrolactone natural products with promising antifouling properties, yet their limited availability constrains further development. Here, we report the identification and characterization of the key biosynthetic enzymes MacE and MacF from the maculalactone (mac) biosynthetic gene cluster in Nodularia sp. NIES-3585. In vitro reconstitution confirmed that MacE catalyzes acyloin condensation between phenylpyruvic acids, while MacF mediates subsequent fusion of the MacE product with cinnamoyl-CoA derivatives. Structure-guided engineering improved enzyme solubility, enabling systematic substrate scope expansion. Through a one-pot enzymatic synthesis, we synthesized 13 maculalactone derivatives with yields reaching more than 96%, while a complementary combinatorial biosynthesis approach enabled the incorporation of sterically demanding indole moieties, thereby significantly expanding the maculalactone structural space. Bioactivity screening against A549 lung adenocarcinoma cells revealed moderate cytotoxicity (IC₅₀ = 20.82–56.64 μM), with methylation of phenol groups significantly enhancing activity. Several analogs exhibited notable antibacterial activity against clinically relevant Gram-positive pathogens, including Streptococcus pneumoniae. Our work provides a sustainable platform for producing structurally diverse maculalactones, laying the foundation for future biomedical applications.